Tesamorelin

Also referred to as Tesamorelin acetate.

Status: FDA-approved for a specific indication. Tesamorelin is FDA-approved for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy, and only in that population. It is not FDA-approved for weight loss in people without HIV-associated lipodystrophy, for general fat reduction, for muscle gain, for athletic use, or for longevity purposes. Any use outside the approved indication is off-label, and compounded tesamorelin preparations used off-label are not covered by the drug's approval. Off-label and compounded status details require ongoing verification.

Tesamorelin is a growth hormone-releasing hormone (GHRH) analogue with one specific FDA approval: reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That approval is narrow and does not extend to general weight loss, general body composition change, athletic performance, or longevity goals in people without this diagnosis. Any other use is off-label. This page separates what the approval actually covers from what patients often hope it means.

What it is

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a peptide that signals the pituitary gland to release growth hormone. It is administered as an injectable product and is one of the few peptides in this category with a completed FDA approval process behind a specific, named indication. The approved product's clinical development was conducted specifically in adults with HIV-associated lipodystrophy, not in the general population.

Why people ask about it

Patients sometimes hear that tesamorelin is 'FDA-approved' and reasonably assume it is a broadly approved fat-loss or general longevity agent. It is not. Interest also comes from people researching growth hormone-axis peptides generally, who encounter tesamorelin because it has more regulatory and clinical documentation than most peptides discussed online.

Proposed mechanism

As a GHRH analogue, tesamorelin is proposed to bind GHRH receptors on the pituitary gland and stimulate pulsatile release of endogenous growth hormone, which in turn increases circulating insulin-like growth factor 1 (IGF-1). In the studied population, this pathway was associated with reductions in visceral adipose tissue specifically. The mechanism by which this translates to fat distribution effects in HIV-associated lipodystrophy is described in the approved product's own clinical pharmacology; it should not be assumed to generalize to unrelated causes of abdominal fat.

What researchers have studied

• Visceral adipose tissue reduction in adults with HIV-associated lipodystrophy
• Effects on IGF-1 levels as a pharmacodynamic marker
• Cardiometabolic markers in the studied lipodystrophy population
• Safety and tolerability in HIV-positive adults on antiretroviral therapy
• Durability of abdominal fat reduction with continued versus discontinued use

Human evidence

• Randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy supported the approval, showing reductions in visceral adipose tissue versus placebo.
• This evidence base is specific to the studied population; it does not establish benefit for weight loss or body composition change in people without HIV-associated lipodystrophy.
• Long-term cardiovascular outcome data in the approved population remain more limited than the abdominal fat endpoint data.
• Evidence for off-label uses (general fat loss, athletic use, longevity) has not been established through the same rigorous, indication-specific process and should not be equated with the approved indication's evidence base.

Preclinical evidence

• Animal studies characterizing GHRH receptor binding and growth hormone secretion informed early development.
• Cell-based receptor binding assays described tesamorelin's pharmacologic activity at GHRH receptors.

What is not yet known

• Whether tesamorelin produces meaningful abdominal or general fat reduction in people without HIV-associated lipodystrophy is not established by the approval.
• Long-term effects of extended off-label use outside the studied population are not well characterized.
• How compounded tesamorelin preparations compare to the approved product in purity and consistency is not something GOAL.MD can verify from published literature.
• Effects on longevity, healthspan, or general aging processes have not been studied in a way that supports any claim in either direction.

Regulatory status and access

An FDA-approved tesamorelin product exists for the specific indication above; compounded tesamorelin is a separate matter and compounding is never itself an FDA approval. Using tesamorelin for any goal outside the approved indication, including general weight loss or body composition, is off-label and would need to be discussed as such. Ask about current availability. Only a physician can determine whether tesamorelin, on-label or off-label, is appropriate after an evaluation.

Known and potential risks

• Growth hormone axis stimulation carries theoretical concerns around glucose handling, and glucose intolerance has been reported in studies of the approved population.
• Injection site reactions are described in product labeling for the approved indication.
• Off-label use in populations that were not studied means the risk profile in those populations is less predictable.
• Compounded tesamorelin, if used off-label, carries the general grey-market and product-quality risks common to any compounded peptide sourced outside the approved supply chain.
• Fluid retention and joint or muscle discomfort have been described with growth hormone axis stimulation generally.
• Any active malignancy is a significant caution given the growth-promoting biology of the GH/IGF-1 axis.

Cautions and who may not be a candidate

• Active malignancy, or a history requiring oncologic surveillance, given the GH/IGF-1 axis mechanism.
• Pregnancy or breastfeeding, where use has not been established as appropriate.
• Disrupted hypothalamic-pituitary axis from pituitary surgery, radiation, or tumor, without specialist input.
• Undiagnosed abdominal or systemic symptoms that have not been medically evaluated.
• Known hypersensitivity to tesamorelin or its components.
• Use for indications outside HIV-associated lipodystrophy without an explicit off-label discussion with a physician.

Questions to discuss with a physician

• Am I in the population for which tesamorelin is actually FDA-approved, or would this be off-label for me?
• What does the approved evidence show, and how does that differ from what is claimed online for general fat loss?
• What has my glucose and IGF-1 status been, and how would that be monitored?
• If this is being considered off-label, what is the reasoning and what evidence supports it for my situation?
• What are the realistic, evidence-based expectations for abdominal fat change if I am in the approved population?
• How would a compounded preparation, if considered, differ from the approved product?
• What monitoring would be recommended over time?

Frequently asked questions

Is tesamorelin FDA-approved?

Yes, tesamorelin is FDA-approved for reduction of excess abdominal fat in adult patients with HIV-associated lipodystrophy. That approval is specific to this population and this indication and does not extend to general weight loss or body composition goals.

Can I use tesamorelin just to lose belly fat if I don't have HIV-associated lipodystrophy?

That would be an off-label use, not covered by the FDA approval. A physician would need to separately discuss the rationale, evidence gaps, and risks of using it outside the approved indication.

Does GOAL.MD sell tesamorelin?

This page is educational and does not constitute an offer to sell or prescribe tesamorelin. Ask about current availability, and only a physician can determine appropriateness after an evaluation.

Is tesamorelin the same as human growth hormone?

No. Tesamorelin is a GHRH analogue that stimulates the body's own pituitary gland to release growth hormone; it is not growth hormone itself.

Does the FDA approval mean tesamorelin is safe for longevity-focused use?

No. The approval is limited to abdominal fat reduction in HIV-associated lipodystrophy. No FDA approval exists for longevity-focused or longevity use, and that claim should not be inferred from the lipodystrophy approval.

What evidence supports the approved use?

Randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy showed reductions in visceral adipose tissue compared with placebo, which supported the approval for that specific population.

Is compounded tesamorelin the same as the approved product?

Compounding is a distinct regulatory pathway from FDA approval. A compounded preparation is not the FDA-approved product, and its quality and consistency depend on the compounding pharmacy; this should be discussed explicitly with a prescriber.

What are the main risks associated with tesamorelin?

Reported considerations include effects on glucose handling, injection site reactions, and fluid retention, among others described in the approved product's studies. A physician can review the full risk profile relevant to an individual.

Who should not use tesamorelin?

People with active malignancy, pregnancy or breastfeeding, disrupted pituitary function, or undiagnosed symptoms generally should not use tesamorelin without specialist evaluation.

Does tesamorelin help with muscle building?

The FDA approval addresses visceral abdominal fat in a specific population, not muscle gain. Any claim about muscle building would be outside the approved indication and outside the evidence that supported approval.

How is tesamorelin different from other growth hormone axis peptides discussed on this site?

Tesamorelin is unusual in this category because it has a completed FDA approval for a specific indication, whereas most other GHRH- or GHRP-class peptides discussed here remain investigational without that regulatory status.

What is Tesamorelin?

Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH), a peptide that signals the pituitary gland to release growth hormone. It is administered as an injectable product and is one of the few peptides in this category with a completed FDA approval process behind a specific, named indication. The approved product's clinical development was conducted specifically in adults with HIV-associated lipodystrophy, not in the general population.

Is Tesamorelin the same as the branded FDA-approved product that contains it?

No. The approved product is a specific manufactured product approved for Reduction of excess abdominal fat in adult patients with HIV-associated lipodystrophy. This is the only approved use; the approval does not cover general weight loss, general body composition improvement, athletic performance, or longevity goals.. Tesamorelin as an ingredient discussed here is not that product, and evidence or labelling for the approved product does not carry over to any other preparation or use.

Does the legal or regulatory status of Tesamorelin tell me whether it works?

No. Regulatory status describes what may lawfully be made, prescribed, or sold, and it is a separate question from what the research shows. On this page the regulatory description and the evidence tiers are kept apart so neither is mistaken for the other.

Can a licensed U.S. compounding pharmacy prepare Tesamorelin?

An FDA-approved tesamorelin product exists for the specific indication above; compounded tesamorelin is a separate matter and compounding is never itself an FDA approval. Using tesamorelin for any goal outside the approved indication, including general weight loss or body composition, is off-label and would need to be discussed as such.

What human evidence exists for Tesamorelin?

Human evidence is well developed for a specific approved indication and does not extend to other uses. Randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy supported the approval, showing reductions in visceral adipose tissue versus placebo.

What have animal and laboratory studies of Tesamorelin reported?

Animal studies characterizing GHRH receptor binding and growth hormone secretion informed early development; Cell-based receptor binding assays described tesamorelin's pharmacologic activity at GHRH receptors. These are animal, tissue, or cell-culture findings. They describe a model, not a demonstrated result in people.

Do the animal findings for Tesamorelin mean it works in people?

No. Findings in animals or in cell culture routinely fail to reproduce in humans, and a positive laboratory model is not evidence of a human benefit. Whether any of this translates to people is exactly what has not been established.

How is Tesamorelin proposed to work?

As a GHRH analogue, tesamorelin is proposed to bind GHRH receptors on the pituitary gland and stimulate pulsatile release of endogenous growth hormone, which in turn increases circulating insulin-like growth factor 1 (IGF-1). In the studied population, this pathway was associated with reductions in visceral adipose tissue specifically. This is a proposed pathway rather than a demonstrated effect.

What is Tesamorelin being studied for?

Published work has focused on Visceral adipose tissue reduction in adults with HIV-associated lipodystrophy; Effects on IGF-1 levels as a pharmacodynamic marker; Cardiometabolic markers in the studied lipodystrophy population; Safety and tolerability in HIV-positive adults on antiretroviral therapy. A research focus describes where questions are being asked, not where answers have been found.

What is still unknown about Tesamorelin?

Whether tesamorelin produces meaningful abdominal or general fat reduction in people without HIV-associated lipodystrophy is not established by the approval; Long-term effects of extended off-label use outside the studied population are not well characterized; How compounded tesamorelin preparations compare to the approved product in purity and consistency is not something GOAL.MD can verify from published literature; Effects on longevity, healthspan, or general aging processes have not been studied in a way that supports any claim in either direction.

What are the risks of Tesamorelin?

Growth hormone axis stimulation carries theoretical concerns around glucose handling, and glucose intolerance has been reported in studies of the approved population; Injection site reactions are described in product labeling for the approved indication; Off-label use in populations that were not studied means the risk profile in those populations is less predictable.

Who should not consider Tesamorelin?

A physician would generally consider it inappropriate in these situations without specialist input: Active malignancy, or a history requiring oncologic surveillance, given the GH/IGF-1 axis mechanism; Pregnancy or breastfeeding, where use has not been established as appropriate; Disrupted hypothalamic-pituitary axis from pituitary surgery, radiation, or tumor, without specialist input; Undiagnosed abdominal or systemic symptoms that have not been medically evaluated.

Is Tesamorelin appropriate during pregnancy or breastfeeding?

No. Pregnancy and breastfeeding are listed as situations where this is not appropriate, because the safety data needed to make that judgement in those populations does not exist.

What would a physician monitor if Tesamorelin were discussed?

Monitoring concepts include Baseline and follow-up assessment of glucose handling given growth hormone axis stimulation; IGF-1 level tracking as a pharmacodynamic marker over time; Periodic reassessment of the original indication and whether continued use remains appropriate. These are concepts a clinician would apply, not instructions for self-directed use.

Are products sold online as Tesamorelin verified?

No. How compounded tesamorelin preparations compare to the approved product in purity and consistency is not something GOAL.MD can verify from published literature. Material bought outside a licensed pharmacy has no verified identity, purity, or sterility.

How would a GOAL.MD physician evaluate a question about Tesamorelin?

A physician starts with the problem you are trying to solve, reviews your history and current medications, and says plainly where the evidence stands. Medical appropriateness is determined only after a full evaluation, and for many substances the honest answer is that the evidence does not support use.

What should I ask a physician about Tesamorelin?

Useful questions include: Am I in the population for which tesamorelin is actually FDA-approved, or would this be off-label for me?; What does the approved evidence show, and how does that differ from what is claimed online for general fat loss?; What has my glucose and IGF-1 status been, and how would that be monitored?; If this is being considered off-label, what is the reasoning and what evidence supports it for my situation?.

Why do people ask about Tesamorelin?

Patients sometimes hear that tesamorelin is 'FDA-approved' and reasonably assume it is a broadly approved fat-loss or general longevity agent. It is not.

Who reviews what GOAL.MD publishes about Tesamorelin?

Clinical content is reviewed by a named physician for medical accuracy and by a second physician for regulatory and compliance language before it is published, and a review byline appears only when that review is recorded. New material stays unpublished until both reviews are on record.

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-13.